Proven in more clinical studies than any other single-injection hyaluronic acid knee therapy, DUROLANE has been shown to be safe and effective.

See additional DUROLANE Resources

During the DUROLANE pivotal trial:13

  • No serious adverse events were considered related to DUROLANE treatment.13
  • The most common adverse events were arthralgia (8.6%), injection site pain (2.3%), and joint swelling (1.7%).13

DUROLANE is safe for repeated courses of therapy. Repeat administration of a course of DUROLANE therapy does not increase the incidence of adverse events.11,13

Choose DUROLANE for Longer-lasting Results

  • Total joint residence time of approximately 150 days based on a half-life of 30 days.48
  • A half-life of 30 days (approximately 4 weeks) in the knee joint in a single-injection treatment regimen35
  • The longest reported half-life of any HA32-35

The clinical relevance of this information has not been determined.